Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Lilly’s Olumiant, spurned by FDA, gets nod from NICE Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a modicum of good news […]
Monthly Archives: June 2017
More consumer woes for Bayer drag down sales, earnings forecasts
More consumer woes for Bayer drag down sales, earnings forecasts On Friday, Bayer announced it would be lowering its earnings forecasts with its second-quarter earnings release—and that consumer health was, […]
Alkermes says it's advancing 'full steam' with schizophrenia candidate
Alkermes says it’s advancing ‘full steam’ with schizophrenia candidate Alkermes has cleared the first major hurdle in its bid to advance schizophrenia candidate ALKS 3831, showing an improvement over placebo […]
Cara tanks after oral pain drug misses mark in phase 2b
Cara tanks after oral pain drug misses mark in phase 2b A phase 2b trial of Cara Therapeutics’ CR845 has missed its primary endpoint. An oral formulation of the kappa […]
Unbowed by Mylan election, mutinous investors renew calls for Coury's exit
Unbowed by Mylan election, mutinous investors renew calls for Coury’s exit Even after Mylan’s investors re-elected the drugmaker’s entire board last week, some aren’t giving up on their demands for […]
IRS investigates patient charity as a possible 'conduit' for Big Pharma sales
IRS investigates patient charity as a possible ‘conduit’ for Big Pharma sales Federal tax investigators have set their sights on patient assistance charity Chronic Disease Fund, which now goes by […]
Atlas rolls out its XI biotech fund, with $350M up for grabs
Atlas rolls out its XI biotech fund, with 0M up for grabs Cambridge venture capital firm Atlas Venture has raised its 11th fund, totaling $350 million, as it looks to […]
Coherus slashes staff by a third after Amgen biosimilar knockback
Coherus slashes staff by a third after Amgen biosimilar knockback The FDA’s rejection of Coherus BioSciences’ biosimilar version of Amgen’s Neulasta means that 51 people at the company will lose […]
Before Iclusig safety flaws went public, ex-Ariad staffer told family to sell shares: feds
Before Iclusig safety flaws went public, ex-Ariad staffer told family to sell shares: feds Two former Ariad employees and one spouse of a former employee are in hot water for […]
As Congress battles over healthcare, Johnson & Johnson CEO says real reform will take time—and cooperation
As Congress battles over healthcare, Johnson & Johnson CEO says real reform will take time—and cooperation While Republican senators work feverishly on a healthcare bill, one prominent pharma CEO says […]